Givaudan's antitrust overhang hasn't gone away - the only 'new' twist is that the US criminal leg may be fading
The Opportunity
Upstream direction is SHORT because antitrust investigations are the definition of multi-year valuation overhang: uncertain fines, uncertain remedies, and a persistent headline risk discount. The nuance is jurisdictional: the upstream research notes a 'partial relief' angle in the US, but keeps the core bearish mechanism intact because EU/UK processes can still drive outcomes. This is not a rumour signal; it is supported by regulator and issuer disclosures, which is why the system treats it as tradeable despite the modest conviction score.
The Timing
Freshness is 60 because the investigation is older in origin but still live, and the tape is crosswind-heavy. For shorts, that argues for respecting squeezes and letting the thesis be carried by event cadence, not by daily tape. Confirmation would look like formal procedural steps (statements of objections, settlement talks, provisioning disclosures). Contradiction would be definitive closure statements across the remaining jurisdictions, not just one leg of the story.
The Evidence
The UK CMA's public announcement explicitly names Givaudan among investigated firms in fragrances and fragrance ingredients ( gov.uk ). Upstream also cites legal press reporting that the US DOJ closed its criminal probe (a de-escalation angle, not a full all-clear) ( law360.com ). Issuer documentation acknowledges multi-jurisdiction investigation exposure ( givaudan.com ).